100m series iconiq growth 1bsawersventurebeat

Writer Secures $100M in Series B Funding to Accelerate Life Sciences Research

The recent announcement that Writer, a San Francisco-based company, has secured $100 million in Series B funding is significant news for the life sciences research community. This substantial investment will enable Writer to further develop its generative AI platform and expand its commercial relationships.

Writer's technology is being rapidly adopted by researchers worldwide, with customers including leading biotech companies such as Gilead, Novo Nordisk, and Regeneron, as well as government agencies like the Food and Drug Administration and the National Institute of Environmental Health Sciences. The company's AI platform combines a knowledge graph with advances in generative AI to enable deep, unbiased scientific exploration.

The funding round was led by ICONIQ Growth, a prominent venture capital firm that has also invested in other successful companies such as Drata and Pinecone. Caroline Xie, General Partner at ICONIQ Growth, will join Writer's board of directors, along with strategic individuals including Alex Gorsky, former Chairman and CEO of Johnson & Johnson, and Olivier Pomel, CEO and Co-Founder of Datadog.

Writer's AI platform is designed to support complex knowledge workflows in life sciences research, accelerating the journey from bench research to therapy launch. Founded in 2018 by CEO Yiannis Kiachopoulos and CTO Artur Saudabayev, Writer has established itself as a leader in the field of biomedical research.

The company plans to use the funding to extend its product lead and expand commercial relationships, further solidifying its position in the life sciences industry. With this significant investment, Writer is well-positioned to drive innovation and advance scientific discovery in the years to come.

100m series iconiq growth 1bsawersventurebeat